睿智医药
(300149)
| 流通市值：50.85亿 | | | 总市值：50.94亿 |
| 流通股本：4.97亿 | | | 总股本：4.98亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 261,261,312.24 | 970,204,758.8 | 718,525,731.65 | 465,164,579.93 |
| 营业收入 | 261,261,312.24 | 970,204,758.8 | 718,525,731.65 | 465,164,579.93 |
| 二、营业总成本 | 260,328,377.29 | 1,031,638,143.67 | 774,216,447.7 | 525,102,424.42 |
| 营业成本 | 189,559,932.03 | 758,697,970.95 | 580,392,041.96 | 389,334,679.48 |
| 利息支出 | - | 0 | - | - |
| 手续费及佣金支出 | - | 0 | - | - |
| 退保金 | - | 0 | - | - |
| 赔付支出净额 | - | 0 | - | - |
| 提取保险合同准备金净额 | - | 0 | - | - |
| 保单红利支出 | - | 0 | - | - |
| 分保费用 | - | 0 | - | - |
| 税金及附加 | 522,015.54 | 5,363,343.8 | 4,077,279.77 | 3,136,583.56 |
| 销售费用 | 11,246,944.27 | 36,406,561.7 | 28,332,227.32 | 21,080,953.73 |
| 管理费用 | 45,776,422.78 | 167,743,905.79 | 108,034,303.98 | 77,678,203.2 |
| 研发费用 | 12,101,507.4 | 59,550,940.69 | 45,275,069.93 | 32,166,317.85 |
| 财务费用 | 1,121,555.27 | 3,875,420.74 | 8,105,524.74 | 1,705,686.6 |
| 其中:利息费用 | 300,332.49 | 26,098,678.68 | 2,911,402.21 | 2,139,821.81 |
| 其中:利息收入 | 2,150,370.32 | 12,158,879.85 | 7,167,883.24 | 4,664,618.03 |
| 加:公允价值变动收益 | -5,444.83 | -2,296,500 | 1,648.56 | 0 |
| 加:投资收益 | 1,941,186.55 | 10,091,924.67 | 7,301,977.95 | 2,500,977.33 |
| 净敞口套期收益 | - | 0 | - | 0 |
| 汇兑收益 | - | 0 | - | - |
| 资产处置收益 | 6,261,722.68 | 8,433,398.14 | 3,621,788.88 | 48,133.97 |
| 资产减值损失(新) | 1,847,630.6 | -156,882,554.07 | -13,627,814.85 | -3,382,513.36 |
| 信用减值损失(新) | -4,817,206.31 | -29,563,544.47 | -14,756,509.91 | -11,877,023.49 |
| 其他收益 | 3,206,031.52 | 14,813,479.08 | 6,591,864.4 | 2,975,994.68 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 9,366,855.16 | -216,837,181.52 | -66,557,761.02 | -69,672,275.36 |
| 加:营业外收入 | 21,116.01 | 67,255.03 | 29,117.39 | 20,154.16 |
| 减:营业外支出 | 64,301.88 | 14,873,936.51 | 510,060.41 | 405,325.86 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 9,323,669.29 | -231,643,863 | -67,038,704.04 | -70,057,447.06 |
| 减:所得税费用 | 2,700,270.94 | -5,131,547.83 | -5,256,354.55 | -7,077,244.96 |
| 六、净利润 | 6,623,398.35 | -226,512,315.17 | -61,782,349.49 | -62,980,202.1 |
| 持续经营净利润 | 6,623,398.35 | -226,512,315.17 | -61,782,349.49 | -62,980,202.1 |
| 终止经营净利润 | - | 0 | - | - |
| 归属于母公司股东的净利润 | 6,642,081.65 | -226,474,828.03 | -61,667,008.36 | -62,906,492.74 |
| 少数股东损益 | -18,683.3 | -37,487.14 | -115,341.13 | -73,709.36 |
| (一)基本每股收益 | 0.01 | -0.45 | -0.12 | -0.13 |
| (二)稀释每股收益 | 0.01 | -0.45 | -0.12 | -0.13 |
| 八、其他综合收益 | -272,754.98 | 3,689,524.72 | -9,433,940.61 | -1,144,800.81 |
| 归属于母公司股东的其他综合收益 | -272,754.98 | 3,689,524.72 | -9,433,940.61 | -1,144,800.81 |
| 九、综合收益总额 | 6,350,643.37 | -222,822,790.45 | -71,216,290.1 | -64,125,002.91 |
| 归属于母公司股东的综合收益总额 | 6,369,326.67 | -222,785,303.31 | -71,100,948.97 | -64,051,293.55 |
| 归属于少数股东的综合收益总额 | -18,683.3 | -37,487.14 | -115,341.13 | -73,709.36 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |